GSK plc (NYSE:GSK) Shares Sold by Farther Finance Advisors LLC

Farther Finance Advisors LLC lowered its stake in shares of GSK plc (NYSE:GSK) by 27.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,055 shares of the pharmaceutical company’s stock after selling 1,530 shares during the quarter. Farther Finance Advisors LLC’s holdings in GSK were worth $137,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Dorsey & Whitney Trust CO LLC boosted its position in GSK by 2.5% during the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company’s stock valued at $389,000 after purchasing an additional 278 shares during the period. Sunbelt Securities Inc. boosted its position in GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after purchasing an additional 302 shares during the period. Rehmann Capital Advisory Group raised its stake in GSK by 6.3% during the 3rd quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock valued at $232,000 after acquiring an additional 332 shares in the last quarter. GC Wealth Management RIA LLC raised its stake in GSK by 2.6% during the 4th quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company’s stock valued at $474,000 after acquiring an additional 353 shares in the last quarter. Finally, Jacobi Capital Management LLC raised its stake in GSK by 3.9% during the 4th quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company’s stock valued at $352,000 after acquiring an additional 389 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Stock Down 0.3 %

GSK opened at $39.44 on Friday. GSK plc has a one year low of $31.72 and a one year high of $45.93. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The stock’s fifty day moving average is $36.53 and its 200-day moving average is $37.00. The company has a market capitalization of $81.62 billion, a PE ratio of 24.80, a P/E/G ratio of 1.12 and a beta of 0.58.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. On average, equities analysts predict that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be issued a $0.3932 dividend. This represents a $1.57 dividend on an annualized basis and a dividend yield of 3.99%. This is a boost from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. GSK’s payout ratio is presently 98.74%.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Morgan Stanley assumed coverage on GSK in a research note on Wednesday, February 12th. They set an “equal weight” rating on the stock. Seven research analysts have rated the stock with a hold rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.